Octafluoropropane
- Generic Name
- Octafluoropropane
- Brand Names
- Definity, Luminity, Optison
- Drug Type
- Small Molecule
- Chemical Formula
- C3F8
- CAS Number
- 76-19-7
- Unique Ingredient Identifier
- CK0N3WH0SR
- Background
Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.
- Indication
Used as an ultrasound contrast imaging in cardiology and radiology.
Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Head and Neck Cancer
- Conditions
- Head and Neck Cancer
- Interventions
- Device: Sonalleve Focused Ultrasound Device
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 20
- Registration Number
- NCT04431648
- Locations
- 🇨🇦
Gregory J Czarnota, Toronto, Ontario, Canada
SONOthrombolysis in Patients With an ST-segment Elevation Myocardial Infarction With fibrinoLYSIS (SONOSTEMI-LYSIS) Trial
- Conditions
- ST Elevation Myocardial Infarction
- Interventions
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 60
- Registration Number
- NCT04217304
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
3-D Super Resolution Ultrasound Microvascular Imaging
- Conditions
- Breast CancerThyroid Cancer
- Interventions
- Device: Acoustic Angiography
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT04136912
- Locations
- 🇺🇸
Univeristy of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States
Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound
- Conditions
- Alzheimer Disease
- Interventions
- Device: Neuronavigation-guided single-element focused ultrasound transducerOther: Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agentsOther: Positron Emission Tomography (PET)Other: Amyvid
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 6
- Registration Number
- NCT04118764
- Locations
- 🇺🇸
Columbia University Irving Medical Center/NYPH, New York, New York, United States
tSCI Contrast Enhanced Ultrasound Study
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 9
- Registration Number
- NCT04056988
- Locations
- 🇺🇸
Harborview Medical Center, Seattle, Washington, United States
Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging
- Conditions
- Kidney Cancer
- Interventions
- Drug: Sulfur hexafluoride lipid microspheres
- First Posted Date
- 2019-07-16
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT04021238
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau
- Conditions
- Von-Hippel LindauKidney Disease, Chronic
- Interventions
- Drug: Sulfur hexafluoride lipid microspheres
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT03907657
- Locations
- 🇺🇸
University of North Carolina of Chapel hill, Chapel Hill, North Carolina, United States
An Ascending Dose Comparison of MVT-100 to Definity in Healthy Volunteers
- Conditions
- Heart Diseases
- Interventions
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Microvascular Therapeutics, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT03882359
- Locations
- 🇺🇸
Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Study to Determine Safety and Dosage of OPTISON in Pediatric Participants
- Conditions
- Transthoracic EchocardiographySuspected or Known Structural or Functional Cardiac Abnormality
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 39
- Registration Number
- NCT03740997
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Lantheus Medical Imaging
- Target Recruit Count
- 160
- Registration Number
- NCT03719612
- Locations
- 🇺🇸
Banner University of Arizona Medical Center, Tucson, Arizona, United States
🇺🇸Cedars Sinai, Los Angeles, California, United States
🇺🇸University of California-Irvine, Orange, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.